Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 31 of the 76 sources its claims cite were checked for support.
Abstract
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatment failure. Tumor expression of interferon (IFN) signaling, high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), and high blood interleukin-6 and ferritin levels were each associated with a lack of durable response. Similar to other cancers, we found that in LBCL tumors, IFN signaling is associated with the expression of multiple checkpoint ligands, including programmed cell death–ligand 1, and these were higher in patients who lacked durable responses to CAR-T therapy. Moreover, tumor IFN signaling and blood M-MDSCs associated with decreased axi-cel expansion. Finally, patients with high tumor burden had higher immune dysregulation with increased serum inflammatory markers and tumor IFN signaling. These data support that immune dysregulation in LBCL promotes axi-cel resistance via multiple mechanistic programs: insufficient axi-cel expansion associated with both circulating M-MDSC and tumor IFN signaling, which also gives rise to expression of immune checkpoint ligands.
Overview
CoChat Summary
TL;DR
In patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), pretherapy immune dysregulation—tumor interferon signaling, circulating monocytic myeloid-derived suppressor cells (M-MDSCs), and elevated inflammatory markers—was associated with lack of durable response. Tumor interferon signaling and M-MDSCs also associated with decreased axi-cel expansion, and high tumor burden was linked to greater systemic and tumor inflammation.
Key findings
- Among 105 axi-cel-treated patients, lack of durable response was associated with tumor interferon signaling, high blood M-MDSCs, and high blood interleukin-6 and ferritin levels.
- Pretreatment tumor biopsies showed higher malignant B-cell PD-L1 and MHC II in nondurable responders; RNA data showed enrichment of the tumor ISG.RS interferon signature in nondurable responders and the T-cell IFNG.GS signature in durable responders. Macrophage-associated genes CD163 (3.4-fold; P = .02) and Siglec-1 (2.9-fold; P < .001) were higher at baseline in nondurable responders.
- Median peak axi-cel levels were 10-fold higher in durable responders than nondurable responders (P = .01); patients with high baseline M-MDSCs (greater than median; 250 cells per μL) had 4-fold lower peak axi-cel expansion (P = .02), and tumor interferon signaling genes were highly expressed in patients with poor axi-cel expansion.
- High tumor burden (>150 mL metabolic tumor volume) was associated with higher ferritin, IL-6, IL-15, TNF-α, and ANG2/ANG1; in public NCICCR LBCL data, high ISG.RS was associated with multiple T-cell inhibitory ligands and with SOCS1 and KLHL6 mutations.
Methods
- Observational study of samples from 105 patients treated with axi-cel: 85 received standard-of-care therapy, 14 as part of a clinical trial, and 6 under the ZUMA-9 expanded access trial. Durable responders remained in remission with a minimum follow-up of 6 months after infusion; nondurable responders died of any cause or relapsed.
- Assays included multiplex immunofluorescence for CD19, CD20, CD3, PD-L1, MHC I, and MHC II (n = 26); NanoString IO360 gene expression (n = 35); RNA-sequencing (n = 18); flow cytometry for M-MDSCs; quantitative polymerase chain reaction for axi-cel expansion; and serum cytokine, ferritin, and CRP measurements.
- Analyses compared durable vs nondurable responders, used gene set enrichment and GSVA for interferon signatures, assessed correlations, and interrogated the public NCICCR-DLBCL data set for ISG.RS-associated features.
Limitations
- Paper-stated: the study was observational and therefore limited to describing associations rather than concluding causal links.
- Paper-stated: multivariable modeling of clinical outcomes using tumor genetics, peripheral blood cytokines, metabolic tumor volume, tumor microenvironment characteristics, and circulating immune subsets would be ideal, but the authors could not analyze every biomarker in each patient because of sample-collection constraints.
- Evident from the text: several assay-specific sample sizes were small (e.g., multiplex immunofluorescence n = 26, NanoString n = 35, RNA-sequencing n = 18, M-MDSC/TME overlap n = 11), and patients were treated across standard-of-care, clinical trial, and expanded-access settings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 1 Not valid · 18 Not checked · 105 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“patients with lymphoma have high levels of circulating myeloid-derived suppressor cells (MDSCs) compared with healthy control subjects”
What the sources say
- Disputedcites [16] Lin, 2011, Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma, Blood sourceExperimental — accuracy not yet measured
The Results distinguish MDSCs from the CD14+HLA-DRlow/− suppressive monocytes studied in lymphoma patients. They report that circulating MDSCs were infrequent and not significantly higher than in healthy controls, contrary to the claim. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [20] Azzaoui, 2016, T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells, Blood sourceExperimental — accuracy not yet measured
The section “MDSCs are expanded in peripheral blood of DLBCL patients” reports significantly higher circulating MDSC counts in patients with diffuse large B-cell lymphoma than in healthy donors. The claim says “patients with lymphoma” generally, while this study’s comparison is limited to that lymphoma subtype; the indexed passage provides no page number. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with active disease experience systemic immune dysregulation detectable in peripheral blood and characterized by elevated cytokines, altered myeloid cell populations, and T-cell deficits.”
What the sources say
- Not checked yetcites [14] Porrata, 2019, Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma, Leuk Lymphoma source
- Partly supportedcites [15] Porrata, 2010, Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio, Am J Hematol sourceExperimental — accuracy not yet measured
The discussion (p. 897) links a high blood neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphoma to inflammation and suggests that immune suppression could lower the absolute lymphocyte count. It does not establish elevated cytokines, altered myeloid-cell populations, or T-cell deficits in patients with active disease; the authors say the proposed mechanism needs prospective study. (LLM, conf=0.86)
- Partly supportedcites [16] Lin, 2011, Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma, Blood sourceExperimental — accuracy not yet measured
The Results and Discussion describe systemic immune suppression in peripheral blood, immunosuppressive monocytes, and reduced T-cell counts or function in patients with B-cell non-Hodgkin lymphoma. The Results report elevated VEGF, but not significantly elevated IL-6, IL-10, CCL-2, or TGF-β; the broad claim of elevated cytokines is therefore not supported. The paper also associates the monocyte phenotype with more aggressive disease rather than establishing the full pattern specifically for all patients with active disease. (LLM, conf=0.88)
- Partly supportedcites [17] Charbonneau, 2012, Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study, Cytokine sourceExperimental — accuracy not yet measured
Results §3.2 reports elevated serum levels of several cytokines in patients with follicular lymphoma or diffuse large B-cell lymphoma compared with controls. Methods §2.2 describes serum cytokine testing, not measurements of myeloid cell populations or T-cell deficits; the paper therefore does not support those parts of the claim. (LLM, conf=0.90)
- Not checked yetcites [18] Seymour, 1995, Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma, J Clin Oncol source
- Not checked yetcites [19] Preti, 1997, Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma, Ann Intern Med source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the pivotal ZUMA-1 trial, the degree of early axi-cel expansion in the peripheral blood associated with a DR.”
What the sources say
- Supportedcites [1] Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol source
The Results report that an ongoing response at 24 months was associated with higher peak CAR T-cell concentrations and greater area under the curve during the first 28 days after axi-cel infusion. The Methods (Procedures; page not available) specify that CAR T-cell concentrations were measured in blood. This supports the claim that greater early peripheral-blood expansion was associated with a durable response. (LLM, conf=0.94)
- Partly supportedcites [2] Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Results (Biomarkers; page not provided) report that early axi-cel expansion in peripheral blood was significantly associated with response. They do not establish an association specifically with durable response (DR); the Discussion describes the association as one with objective response. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
What the sources say
- Could not verifycites [2] Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
Our copy of the ZUMA-1 trial (Neelapu et al. 2017, NEJM) addresses axi-cel efficacy, CAR T-cell expansion, cytokine-release syndrome and neurologic events; no passage mentions an interferon-stimulated gene signature (ISG.RS), interferon types, or a multigenic therapy-resistance program. Searched: 'ISG.RS interferon-stimulated gene signature therapy resistance', 'interferon gene expression tumor resistance program multigenic', and 'interferon signature gene expression tumor cell-of-origin resistance to therapy' — the top hits were the Results/Biomarkers and Discussion sections on serum cytokines (IL-6, -10, -15, -2Rα, GM-CSF, ferritin) and the reference list. The closest gene-expression content is the Methods (End Points and Assessments) noting cell-of-origin subtype by the NanoString Lymphoma Subtyping Test, which says nothing about interferon-driven resistance. Our copy neither supports nor contradicts the claim, and it credits the point to no other work. (LLM, conf=0.75)
- Partly supportedcites [24] Benci, 2016, Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell sourceExperimental — accuracy not yet measured
Our copy supports the core idea: tumor IFN signaling (type I and II, via STAT1) drives a 'multigenic resistance program' of TCIR ligands plus ISGs, which the authors define as IDILS (PDL1, TNFRSF14, LGALS9, MHCII, CD86, IFIT1, MX1) and which associates with clinical progression after anti-PD1 (RESULTS 'A Multigenic Resistance Program of TCIR Ligands and ISGs'; RESULTS 'High Expression of ISGs Can Associate with Clinical Progression After Anti-PD1'; DISCUSSION). However, the term 'ISG.RS' never appears in our copy (no exact-phrase hits; searches for 'ISG.RS' and 'coordinately activated' returned only semantic neighbours), and the ISG component is explicitly credited to another work — the 'ISGs that we previously described to be robustly expressed across human cancers (Weichselbaum et al., 2008)'. The claim's signature name and its framing that the signature itself activates resistance (rather than IFN/STAT1 signaling driving IDILS, with ISGs as correlative biomarkers) are therefore not stated by this paper. (LLM, conf=0.70)
- Partly supportedcites [54] Twyman-Saint Victor, 2015, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature sourceExperimental — accuracy not yet measured
Our copy supports only part of this: the main text (Abstract/Results, Fig. 1g, Extended Data Fig. 2e) reports that transcriptomic profiling of resistant tumors (Res 499/177, Res 237) defined a multigenic RT + anti-CTLA4 'resistance gene signature' that includes PD-L1 together with interferon stimulated genes, and that PD-L1 was co-expressed with that signature in a metastatic melanoma patient cohort. However, the paper never names or defines a signature 'ISG.RS', never states that its genes are coordinately activated by multiple types of IFN (IFN-gamma is used only experimentally to induce PD-L1, and type I IFN is credited to separate LCMV works, refs 10-11), and it bounds the resistance program to resistance against radiation plus CTLA4 blockade rather than 'therapy resistance' generally. The claim's causal framing ('when tumors express ... a resistance program is activated') also exceeds the correlative gene-profiling evidence the paper presents, and the paper instead identifies elevated PD-L1 as the dominant resistance mechanism, with ISGs described only as genes that 'may promote immune suppression through PD-L1'. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results suggest that a subset of LBCLs rely on tumor IFN signaling to mediate T-cell exhaustion and defend against antitumor immunity.23”
What the sources say
- Partly supportedcites [23] de Charette, 2018, Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy, Haematologica sourceExperimental — accuracy not yet measured
Our copy of de Charette et al. 2018 supports the surrounding elements of the claim but not its causal mechanism: the 'Defend' section (Inhibition / killing of immune cells) states that a subset of large B-cell lymphomas — DLBCL, more often ABC than GC (PD-L1 36% / 4% ; PD-L2 60% / 26%), PMBL (71%) and immune-privileged DLBCL with 9p24 alterations — inhibit T cells through PD-L1/PD-L2, LAG-3/MHC-II and HLA-G, and the Immunosuppressive microenvironment > Cytokines passage (p. n/a) describes an exhausted CTL phenotype (high PD-1 and TIM-3) in B-cell NHL. However, that exhaustion is attributed to tumor/microenvironment TGF-β (ref 123), not to tumor interferon signalling: five searches of our full-text copy (interferon, IFN, IFN-γ/type I IFN, JAK-STAT, tumor IFN signaling) returned no passage stating that tumor IFN signaling mediates T-cell exhaustion in LBCL — the only JAK reference is JAK2 within the 9p24 amplicon driving PD-L1/PD-L2 transcription. So the IFN-signaling element of the sentence is not supported by this source. (LLM, conf=0.68)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
78 more claims · 2 with their cited sources checked
Create a free account to see all 139 claims and to verify the 45 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The loss of antitumor efficacy has been attributed to CAR-T cell exhaustion in the tumor microenvironment17,18, or, to a lesser extent, immune evasion of malignant cells with loss of tumor surface antigen expression19.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“We compared TME gene expression according to NanoString in patients with a high ferritin level (>1000 ng/mL; n = 8) vs patients with lower ferritin levels (<1000 ng/mL; n = 28).”
§ Results
“We therefore used a NanoString limited gene expression panel enriched for genes of the TME on pretreatment biopsy specimens (n = 35).”
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationGenetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationInterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Self-citationChapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Cited by
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
“Leukopenia‡ 55 (32) 50 (29) 43 (26) 37 (22)”
Self-citationRejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Vitanza, N. A., Wilson, A. L., Huang, W., Seidel, K., Brown, C., Gustafson, J. A., Yokoyama, J. K., Johnson, A. J., Baxter, B. A., Koning, R. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0750 · Cited by 279
“DIPG tumors may also recruit immunoregulatory microglia and myeloid populations that limit CAR T-cell efficacy (54) as our MRM-MS data revealed heightened Figure 6.”
ResultDistinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citation
Metadata
- Authors
- Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., Cao, B., Chavez, J. C., Shah, B., Lazaryan, A., Nishihori, T., Hussaini, M., Gonzalez, R. J., Mullinax, J. E., Rodriguez, P. C., Conejo-Garcia, J. R., Anasetti, C., Davila, M. L., & Locke, F. L.
- Affiliations
- Department of Blood and Marrow Transplant and Cellular Immunotherapy,
- Department of Clinical Science,
- Department of Bioinformatics and Biostatistics,
- Department of Malignant Hematology,
- Department of Pathology,
- Department of Sarcoma, and
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL
- University of South Florida (US)
- Corresponding author
- Jain, Michael D.
- Zhao, Hua
- ORCID
- Jain, Michael D.
- Zhao, Hua
- Wang, Xuefeng
- Atkins, Reginald
- Menges, Meghan
- Reid, Kayla
- Faramand, Rawan
- Bachmeier, Christina
- Dean, Erin A.
- Cao, Biwei
- Shah, Bijal
- Lazaryan, Aleksandr
- Nishihori, Taiga
- Gonzalez, Ricardo J.
- Mullinax, John E.
- Rodriguez, Paulo C.
- Conejo-Garcia, Jose R.
- Anasetti, Claudio
- Davila, Marco L.
- Locke, Frederick L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-05-13
- Volume
- 137
- Issue
- 19
- Pages
- 2621-2633
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC8120145
- OpenAlex
- W3123125599
- Semantic Scholar
- be4a1f2554f696107aa788eb12aaa850563c1cf0
- Cited by
- 297
- References
- 60
- Citations by year
- 2026: 40 · 2025: 63 · 2024: 54 · 2023: 72 · 2022: 43 · 2021: 23
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA184185, K23CA201594, P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- large B-cell lymphoma, axicabtagene ciloleucel, CAR T-cell therapy, treatment failure, interferon signaling, myeloid-derived suppressor cells, immune checkpoint ligands, PD-L1, interleukin-6, ferritin, immune dysregulation, CAR-T cell expansion, tumor burden, relapsed/refractory lymphoma
- MeSH terms
- Myeloid-Derived Suppressor Cells, Receptors, Chimeric Antigen, Adult, Aged, Biological Products, Female, Ferritins, Humans, Interferons, Male, Middle Aged, RNA, Neoplasm, Cytokines, Immunotherapy, Adoptive, Lymphoma, B-Cell, Treatment Failure, Tumor Escape, Tumor Burden, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood.2020007445
- The paper
- Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., Cao, B., Chavez, J. C., Shah, B., Lazaryan, A., Nishihori, T., Hussaini, M., Gonzalez, R. J., Mullinax, J. E., Rodriguez, P. C., . . . Locke, F. L. (2021). Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. https://doi.org/10.1182/blood.2020007445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.